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ROBERT H. BARTH and NICHOLAS DEVINCENZO
Nephrology Section, VA Medical Center, and State University of New York Health Science Center at Brooklyn, Brooklyn, New York, USA
Use of vancomycin in high-flux hemodialysis: Experience with 130
courses of therapy. Vancomycin is often administered to hemodialysis
patients at long dosage intervals because its removal by hemodialysis is
considered to be negligible. We and others, however, have demonstrated
significant removal of vancomycin by high-flux hemodialysis. This report
describes our experience with 89 courses of vancomycin using a revised
regimen with a loading dose followed by 500 mg doses after each dialysis
treatment, and compares results with 41 courses using single weekly
dosing. All patients were dialyzed with high-flux membranes using volu-
metric ultrafiltration and bicarbonate dialysate. Serum vancomycin levels
were obtained two hours after completion of infusion (peak) and imme-
diately prior to dialysis (trough) and were measured by Abbot TD
fluorescence polarization immunoassay. Duration of multiple-dose ther-
apy was 11 8 days, with mean total dose 3.6 1.8 g. Initial doses of 20
mg/kg rapidly and reliably established therapeutic pre-dialysis serum levels
(10 to 25 j.g/ml). In patients treated with multiple dosing, 431 pre-dialysis
levels were obtained. The mean level was 15.9 5.7 tg/ml; 55 levels
(13%) were less than 10 jrg/ml and 22 (5%) were above 25 jg/ml. In
patients treated once weekly, 77% of levels were below 10 .tg/ml by five
days after administration, and 84% at one week. No patient developed
demonstrable ototoxicity. Twenty-five patients were treated for  two
weeks, five for  four weeks, and two for >five weeks, with no evidence
of toxic accumulation. Mean peak level was 20.1 4.6 g/ml, with a mean
difference from preceding pre-dialysis level of 7.2 2.2 rg/ml. We
conclude that in high-flux hemodialysis, a 20 mg/kg loading dose of
vancomycin followed by 500 mg doses after each dialysis treatment
achieves predictable, adequate and safe therapeutic levels, does not lead
to unacceptably high peaks, and does not accumulate during long treat-
ment courses. By contrast, once-weekly vancomycin dosing resulted in
subtherapeutic serum levels after five to seven days, and should be
abandoned in the high-flux setting.
Vancomycin is frequently administered to patients on hemodi-
alysis because of its activity against gram-positive organisms—
probably the most common infecting agents in chronic dialysis
patients [1—7]. It is excreted almost entirely by glomerular filtra-
tion, and the elimination half-life, which is approximately nine
hours with normal renal function [8, 9], in end-stage renal disease
is markedly prolonged to between 54 and 180 hours [9—131. Since
the clearance of vancomycin by hemodialysis has been considered
negligible, this prolonged half-life should allow the use of admin-
istration schedules with quite long dosage intervals, and single
weekly doses of one gram have been used for more than a decade.
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Recent investigations in our and other centers, however, have
indicated that use of new high-permeability dialysis membranes
results in significant removal of vancomycin [12—25].
Our own experience [12, 18, 20] has indicated a marked (33.5
2.4%) reduction in serum vancomycin levels during dialysis using
large surface area high-flux dialyzers, leading to persistently low
(< 10 gIml) serum levels during the week between 1000 mg
doses, and we have frequently observed susceptible gram-positive
infections that failed to respond readily to vancomycin therapy.
Nevertheless, a role for vancomycin in the empiric treatment of
infections in dialysis patients seems indisputable: in the last 125
gram-positive bacteremic infections in our center, 95% showed in
vitro susceptibility to vancomycin. No other bactericidal antibiotic
was effective on more than 53% of isolates (Fig. 1) [6].
We therefore instituted a revised regimen for vancomycin
therapy [18] using a loading dose followed by 500 mg doses after
each dialysis treatment. This report describes the pharmacoki-
netic experience with 89 courses of therapy using this revised
dosing strategy, and compares results obtained with 41 courses
using single weekly dosing.
Methods
Patients
One hundred thirty courses of vancomycin (cases) were admin-
istered to 69 men and 1 woman (patients) between January 1990,
and September 1995. All were receiving chronic maintenance
hemodialysis; 32 (46%) were diabetic. The mean patient age was
64.0 11.6 years and mean weight was 70.3 14.3 kg.
Hemodialysis
All patients were dialyzed with high flux dialyzers, as shown in
Table 1, at blood flow rates of 400 to 600 mI/mm, using volumetric
ultrafiltration dialysis systems (Monitral, Fresenius) and bicarbon-
ate dialysate. Dialysis frequency was twice weekly in 29 cases
(interdialytic interval 3,3 0.4 days) and three times weekly in
101 cases (interdialytic interval 2.3 0.2 days), with a session
duration of 3.3 0.4 hr. Urea reduction ratio (URR), measured
during 116 courses of therapy, was 63.6 8.3%.
Vancomycin administration
In all cases, vancomycin was administered in the hemodialysis
unit for a therapeutic indication (Table 2); in some cases, more
than one indication was present. The drug was diluted in 100 to
250 ml 0.45% NaCl and administered as an intravenous infusion
over 30 to 60 minutes, following the completion of hemodialysis.
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Vancomycin
Tetracycline
Clindamycin
Trimeth-Sulfa
Ciprofloxacin
Amp/Sulbactam
Cephalothin
Oxacillin
Erythromycin
Penicillin G
___ .___ I
Dialyzer
(manufacturer) Type" Membrane
Surface
area KA" N
F60 HF Polysulfone 1.2 rn2 532 13
(Fresenius)
F80 HF Polysulfone 1.8 m2 572 94
(Fresenius)
Bi 2.1U HF Polymethylmethacrylate 2.1 m2 651 4
(Toray)
Biospal PP Sulfonated 1.0 m2 243 3
(Hospal)
Filtral 12 HF
polyacrylonitrile
Sulfonated 1.2 m2 323 2
(Hospal)
Filtral 16 HF
polyacrylonitrile
Sulfonated 1.7 m2 436 17
(Hospal) polyacrylonitrile
Total 133
In 41 cases, patients received a single dose of vancomycin, while
in 89 cases patients received a loading dose followed by 500 mg
after every successive dialysis until therapy was complete. During
the first two years of the investigation the initial dose in both
groups was 1000 mg, and in 1993 the initial dose was changed to
20 mg/kg.
Vancomycin serum levels
Peak serum vancomycin levels were drawn two hours after the
end of the infusion to ensure completion of the distribution phase
[26—28]. "Trough" levels were drawn prior to the initiation of
successive hemodialysis treatments. In patients treated with a
single dose, levels were measured for at least one week. In
patients receiving multiple doses, levels were measured until the
dialysis treatment following the last dose. Since not all patients
were dialyzed with the same schedule, numbers of data points
differed at different times following the initial dose. All levels were
assayed using the TD fluorescence polarization immunoassay
(Abbot Diagnostics, Irving, TX, USA) [291.
Multiple
dose
Single
dose
Fever 29 18
Bacteremia
Enterococcal 3 0
Pneumococcal 1 0
Staphylococcal 14 2
Soft-tissue infections 9 5
Vascular access infections 13 1
Percutaneous catheter infection 9 3
Respiratory infection 4 3
Urinary tract infections 2 3
Endocarditis prophylaxis (dental procedures) 0 3
Endocarditis 3 0
Osteomyelitis 1 0
Table 3. Initial vancomycin dose
Initial Initial
dose mg dose mg/kg N"
Single dosing
20 mg/kg 1296 250 19.6 1.7 28
1000 mg 1000 14.9 3.3 27
Overall 1198 247 17.3 3.7 40
Multiple post-hemodialysis
dosing
20 mg/kg 1367 262 19.9 1.7 57
1000 mg 1000 15.4 3.2 37
Overall 1203 326 17.3 4.1 89
Statistics
Non-parametric (Mann-Whitney U-test) or parametric (t-test)
analysis of differences between group means were carried out as
appropriate. Comparison of frequency distributions was carried
out using the chi-square test with Yates correction for continuity.
Unless otherwise specified, data are reported as mean so.
Results
Vancomycin was administered using the multiple post-dialysis
dosing regimen to 89 patients, who received from 2 to 24 doses
each (median 5), for a mean total dose of 3.6 1.8 g (range 1.5
to 13.2 g). The mean duration of therapy was 11 8 days (range
3 to 54 days). Single weekly doses were administered to 41
patients. Initial doses in both groups were similar (Table 3). There
were no differences between patients in the single-dose and
multiple-dose groups with respect to age, weight, URR, or
percentage of diabetics. The patients treated with a single dose
had a longer interdialytic interval (2.7 0.5 vs. 2.5 0.4 days, P <
0.02) and fewer weekly hours (8.8 1.9 vs. 9.7 1.7 hr, P < 0.01)
of dialysis than the patients who received multiple dosing.
The initial vancomycin dose in mg/kg body wt was strongly
correlated with the serum level at 48 hours (Fig. 2). In the group
of patients given multiple doses, a loading dose of 20 mg/kg
resulted in more rapid achievement of levels greater than 10
xg/ml during the first week than did a loading dose of 1000 mg. In
the 20 mg/kg group, 6 of 92 levels (7%) during the first five days
of therapy were below 10 jxg/ml, while in the 1000mg group, 17 of
56 (30%) were less than 10 xg/ml (P < 0.001). By seven days after
Table 2. Indications for vancomycin therapy
0% 25% 50% 75% 100%
Percent of susceptible isolates
Fig. 1. Antibiotic susceptibilities of organisms isolated from 125 consecutive
cases of gram-positive bacteremia at the Brooklyn VAMC hemodialysis unit.
Table 1. Dialyzers used
"Some overlap is present, since in some patients a dose of 20 mg/kg was
actually 1000 mg
"HF = hollow fiber, PP = parallel plateh K0A calculated from direct quantification of dialysate urea
"In 3 cases more than one dialyzer was used during a course of therapy
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<5 5—10 10—25 >25
Serum vancomycin level, .tg/mI
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Initial vancomycin dose, mg/kg
Fig. 2. Pre-dialysis serum vancomycin levels 48 hours after administration,
as a function of initial dose, N = 56. The equation of the regression line is
y = 0.75x + 1.33; r = 0.49 (P < 0.001).
0 1 2 3 4 5
Days from initial dose
Fig. 3. Mean pre-hemodialysis serum vancomycin level SEM for patients
treated with multiple 500 mg post-dialysis doses and either a 20 mg/kg (•,
N = 50) or a 1000mg (Y, N = 36) loading dose. *P < 0.02; * *P < 0.01 for
differences between mean values. Dotted line indicates the lower limit of
the therapeutic range.
Fig. 4. Distribution of vancomycin levels at five days (first bar) and seven
days (second bar) after initial dose. Symbols are: (LI) patients given single
weekly doses; and () those given multiple post-dialysis doses. For single
doses, N = 13 at five days, N = 25 at seven days. For multiple doses, N =
41 at five days, N = 57 at seven days. *P < 0.025, < 0.005, <
0.001 for difference from single dose therapy.
0 1 2 3 4 5
Days from initial dose
Fig. 5. Mean pre-hemodialysis serum vancomycin level SEM through one
week of therapy in patients treated with a single weekly dose (0, N = 41) or
with a loading dose followed by multiple 500 mgpost-hemodialysis doses (•
N = 89). * < 0.02; < 0.001 for differences between mean values.
Dotted line indicates the lower limit of the therapeutic range.
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the loading dose, there was no longer a difference in the distri-
bution of levels in patients given initial doses of 1000 mg or 20
mg/kg. Figure 3 shows the mean pre-dialysis serum levels for
patients given multiple doses with a 20 mg/kg loading dose and
with a 1000 mg loading dose. In patients receiving a single weekly
dose, the mean levels were somewhat higher throughout the week
in the group receiving 20 mg/kg, but the differences were not
statistically significant.
At five days and one week after the initial dose, levels were
distributed as shown in Figure 4. At five days after administration,
single-dose therapy resulted in serum levels which were below 10
xg/ml in 77% of cases and below 5 xg/ml in 30%. At one week,
levels were less than 10 .rg/ml in 84% and less than 5 rg/ml in
28%. By contrast, in patients treated with multiple doses only 12%
were below 10 xg/ml at five days and 16% at one week, and only
one of 98 serum levels obtained at five days and one week was less
than 5 jxg/ml. A comparison of levels through the first week of
therapy in patients given single and multiple doses is shown in
Figure 5.
Overall, in patients treated with multiple doses, 60.6% of 431
pre-hemodialysis trough levels fell between 10 and 20 j.rglml, and
82.8% were between 10 and 25 jxg/ml, while only 12.1% were
below 10 .Lglml. Twenty-five patients were treated for  two
weeks, 5 for  four weeks, and 2 for > five weeks, with no
evidence of toxic accumulation of vancomycin. Only 22 of 431
trough levels (5,1%) exceeded 25 jig/mI. The histogram in Figure
6 shows the overall distribution of serum levels in patients treated
with multiple dosing. Figure 7 shows the mean serum vancomycin
levels SD through 21 days for all patients treated with multiple
dosing. In the five patients treated with multiple doses for four
932 Barth and DeVincenzo.' Vancomycin therapy in high-flux HD
SD
ØøØøø/ØIøø/ØVØ
1I1IøøIIII1I
5 10 15 20 25 30 35
Vancomycin serum level, mg/mi
Fig. 6. Histogram showing distribution of pre-hemodialysis serum vancomy-
cm levels in patients treated with multiple 500 mg post-dialysis doses. Lines
indicate mean SD.
weeks or more, mean serum level during the period from days 22
to 45 was 18.6 3.7 xg/ml (range 10.4 to 27.7, N = 29).
Serial peak levels (N = 18) were measured in six patients two
hours after 500 mg doses. The overall mean peak level was 20.1
4.6 jxg/ml (range 12.2 to 29.8), and mean difference from preced-
ing pre-dialysis level was 7.2 2.2 xg/ml (range 3.8 to 11.7).
Figure 8 shows mean serial changes in serum vancomycin level
through one hemodialysis cycle.
Infection resolved in almost all patients. In the multiply dosed
group, two patients required surgical excision of an infected PTFE
graft, one required removal of a percutaneous catheter, and one
had relapse of staphylococcal endocarditis.
"Red man syndrome" occurred five times, and resulted irs
discontinuation of therapy in one case. There were no other
symptoms attributable to vancomycin. Audiometry performed in
two patients with maximum trough levels of 23.0 and 23.7 xg/ml
revealed no hearing loss.
Discussion
Evaluation of vancomycin dosing regimens is rendered prob-
lematic by the scarcity of data relating serum levels to therapeutic
efficacy [28, 30—35]. In fact, the original recommended ranges for
peak (30 to 40 j.Lg/ml) and trough (5 to 10 jxg/ml) levels were
based on an estimation of serum levels which could be expected
with the entirely empirical "standard" vancomycin regimen of 2
g/day in a 70 kg man with normal renal function, rather than on
data regarding efficacy or toxicity [28, 36]. Much is known,
however, about the pharmacokinetics and pharmacodynamics of
vancomycin, and some conclusions may he drawn regarding
desirable levels in dialysis patients.
The target of therapy with vancomycin in the majority of cases
is a presumed or definite infection with staphylococci. Data from
several sources indicate that the bactericidal activity of vancomy-
cm against these organisms is not concentration dependent once
the minimal inhibitory concentration (MIC) has been exceeded,
and that high peak levels are not therefore necessary for thera-
peutic efficacy [37—39]. Monitoring of peak levels thus serves
primarily to prevent toxicity, especially ototoxicity [40]. Ototoxic-
ity from vancomycin alone appears to be extremely rare [30—32,
41], however, so much so that the necessity for monitoring peak
levels at all has been questioned [30—32, 40, 42—44]. In any case,
maintaining peak levels less than 40 to 50 xgIml (measured 1 to 2
hr after the completion of infusion) should almost certainly
prevent the occurrence of any irreversible hearing loss.
Given the low likelihood of vancomycin toxicity, especially in
the dialysis patient who is not susceptible to nephrotoxicity, the
focus of pharmacokinetic monitoring should be on assuring that
vancomycin serum levels do not drop below a therapeutically
effective threshold. The MIC for most staphylococcal species is
between 0.1 and 5.0 xg/ml [45, 46], although there have been
increasingly frequent observations of higher MICs, especially in
coagulase-negative species [47, 48]. MICs and minimal bacteri-
cidal concentrations (MBCs) may also be much higher in the
presence of catheters or other foreign material [49—52], including
polytetrafluoroethylene [53], the material used for almost all
prosthetic arteriovenous fistulas in dialysis patients. Effectiveness
of vancomycin in serum is lessened by its 40 to 60% protein
binding [54], and tissue drug levels may be substantially lower than
simultaneous serum levels: 52% in heart valves, 30% in subcuta-
neous tissue, 27% in muscle [55], 17% in pulmonary alveolar fluid
[56], and 15% in bone [57]. A trough serum level of 5 p.g/ml may
therefore frequently be inadequate to eradicate staphylococci
from a tissue site, especially in the presence of a catheter or
prosthetic dialysis access.
A further consideration in dialysis patients is the cross-reactivity
in the commonly used TD fluorescence polarization immunoas-
say of an inactive vancomycin metabolite, CDP-1, which accumu-
lates over time and may lead to an overestimation of serum
vancomycin levels by as much as 40% [42, 58—61]. Thus, when
measured by this assay, levels that appear to be in the therapeutic
range may in fact fall short.
The need for trough levels higher than the originally proposed
5 to 10 xg/m1 has been reflected in recommendations made by a
number of authors based on theoretical or clinical considerations
(Table 4). There have also been two recent reports in which
outcome in infections treated with vancomycin was found to be
related to trough levels [66, 67]. More rapid resolution of fever
and leukocytosis in patients with gram-positive bacteremia was
associated with trough vancomycin levels greater than 10 jxg/ml in
one [66], and in the second mean trough vancomycin levels of less
than 12 jxg/ml predicted relapse of gram-positive peritonitis in
patients on peritoneal dialysis [67]. Finally, because of the ex-
tremely prolonged half-life of vancomycin in end-stage renal
disease, serum levels in dialyzed patients approximate a continu-
ous infusion; several authors have recommended a steady-state
level for continuous therapy of 15 jxg/ml [68, 69].
Considering all of the above data, we believe trough levels
below 10 jig/mI to be probably therapeutically inadequate in
dialysis patients, that the desirable range for trough (pre-dialysis)
serum vancomycin levels should be 10 to 20 jig/mI, and that peak
levels less than 40 jig/mI are acceptably safe.
Examining the results of 500 mg post-dialysis doses of vanco-
mycin in this context, we found that single weekly doses produced
serum levels which were likely to be subtherapeutic by five days
following administration of the drug. Table 4 shows that in
patients given single weekly doses, 77% of serum vancomycin
levels were less than 10 jig/mi by five days after dosing and 31%
were below 5 jig/mI. The use of a 20 mg/kg dose rather than the
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36 42 48 preceding trough value was 7.2 2.2 xg/ml. Saunders measured
165 paired trough-peak values in patients treated with vancomy-
cm, and found a mean increase of 16.6 jxg/ml [40], but the patients
were not on dialysis, and doses ranged from 500 to 1500 mg.
Nonetheless, Saunders' data probably define the upper limit value
for rise in level after a dose; it is unlikely that patients on high-flux
dialysis would ever achieve this degree of increase, since a dialysis
is performed between the "trough" level and the following peak,
with significant removal of vancomycin. Our trough levels were
not true troughs, in the sense of the level immediately preceding
a dose, but they were presumably the lowest serum levels during
a long (24 to 96 hr) interdialytic period, and thus in practical terms
the lowest level attained during more than 90% of the interval
between doses. Using pre—dialysis levels as troughs avoids the
uncertainty introduced by the dialytic removal of vancomycin
from the intravascular space and subsequent rebound of unpre-
dictable timing and degree as the drug is redistributed from the
peripheral compartment [13, 16, 22]. Our peak levels should
represent true peaks, since by three hours after the completion of
dialysis when they were drawn, most of the rebound effect is
complete.
There were 22 trough levels (5%) in our patients that were
greater than 25 xg/ml (range 25.2 to 35.0 jxg/ml, median 27.8jxg/ml), which might raise some concern about potential toxic
levels after the following dose. Even if a rise in level similar to that
described by Saunders in undialyzed patients were to be obtained,
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Fig. 7. Mean pre-hemodialysis serum
21 vancomycin level SD through three weeks of
therapy for all patients treated with multiple 500
mg post-dialysis doses.
Table 4. Recommended trough serum vancomycin levels
0 7 14
Days from initial dose
30
— 25
- 20
0
E 1500
>
E
a) 5(I)
0
50
45
403530
Eo 250
n 20
>
E 15
=
10
ci)
5
0
Fig. 8. Mean serum vancomycin level SEM through 1 hemodialysis cycle in
14 cases. a, pre-hemodialysis; b, post-hemodialysis; c, 15 minutes after
completion of vancomycin infusion; d, two hours after completion of
infusion; e, prior to next hemodialysis. N = 14.
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"standard" 1000 mg weekly dose did not improve results: at one
week 13 of 16 levels (81%) were below 10 xg/ml and 4 of 16(25%)
were less than 5 ag/ml. In contrast, in patients given 500 mg after
each dialysis, only 12% of levels were below 10 xg/ml at five days
and 18% at seven days, and in only one instance out of 98 levels
measured at five and seven days was the serum level below 5
xg/ml. An initial dose of 18 to 22 mg/kg more rapidly and more
reliably led to levels in the therapeutic range than lower loading
doses. Overall, 47 of 433 levels (11%) measured in multiply-dosed
patients were less than 10 jxg/ml and only 5 of 433 (1%) were
below 5 jig/mI (Fig. 2). Adequate therapeutic levels were thus
consistently achieved by this regimen.
Apart from a few episodes of the anaphylactoid "red man"
reaction, there was no clinically overt toxicity attributable to
vancomycin. Eighteen peak levels were measured two hours after
completion of the infusion, and the range was 12.2 to 29.8 jig/mI,
with a mean value of 20.1 4.6 jig/mI. Mean increase from the
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however, the following peaks would have been 42 to 52 xg/ml, for
the most part within recommended limits for peak levels. More-
over, as discussed above, so great a rise would be unlikely.
We are unable to comment on differences in outcome between
the multiply dosed and single dosed groups, since no attempt was
made to randomize patients to the various therapeutic strategies.
Given the need for surgical intervention in three of the patients
treated with multiple doses, the single dose group might have
seemed to do better. However, this is at least in part because
patients who received single dose therapy were selected to have
less severe disease. We did not feel it ethically defensible to treat
a severe, deep staphylococcal infection with single weekly dosing.
In fact, many of the patients who received weekly dosing were
treated for superficial soft-tissue infections or endocarditis pro-
phylaxis for dental procedures (Table 2).
Despite limitations on vancomycin use necessitated by the
increasing emergence of resistant strains of gram-positive bacte-
ria, especially enterococci [70, 71], this antibiotic remains ex-
tremely important in the therapy of bacterial infections in patients
on hemodialysis. The large majority of those infections are caused
by gram-positive organisms [1—7], and in many institutions, includ-
ing our own, the prevalence of methicillin-resistance is high
among both coagulase-positive and negative Staphylococci (Fig.
1), making vancomycin a compelling choice for initial therapy of
apparent systemic infections. Further, the therapy of serious
gram-positive infections in dialysis patients is frequently compli-
cated by extreme difficulty in maintaining intravenous access. In
such situations, the ability to administer vancomycin every 48 to 72
hours via the hemodialysis line is a very great advantage, and its
choice is again favored, even though it may be less rapidly
bactericidal for staphylococci than are beta-lactam agents [72—74].
Given the serious nature of the frequent systemic staphylococ-
cal infections in dialysis patients, and the extreme rarity and
dubious dose-dependency of vancomycin toxicity [35], it is crucial
to maintain effective serum levels throughout therapy, while
limiting peak concentrations is less important. In patients treated
with high-flux hemodialysis, the vancomycin regimen presented
here—a loading dose of 20 mg/kg followed by 500 mg after each
hemodialysis treatment—rapidly achieved pre-dialysis trough se-
rum levels of between 10 and 15 jxg/ml, and resulted in plateau
steady-state trough levels between 15 and 25 xg/ml after two to
three weeks. Peak levels following the 500 mg doses were 5 to 10
j.tg/ml higher than pre-dialysis trough levels and rarely exceeded
35 xg/ml. Once-weekly dosing with 1000 mg or with 20 mg/kg led
to levels which are probably subtherapeutic (< 10 xg/ml) in over
75% of cases by five days after administration, and in 84% of cases
at one week. Even using the more conservative threshold value of
5 xg/ml, 30% of serum levels were subtherapeutic five days after
a single vancomycin dose.
Most of the previously published investigations of vancomyein
in high-flux dialysis have been short-term studies of pharmacoki-
netics in small numbers of patients; only two have studied multiple
dosing during actual therapeutic use for periods longer than one
week (18, 241, and in both of those studies only a small number of
patients was treated. In a pharmacokinetic study in of eight
uninfected dialysis patients, Pollard et al [13] concluded that
single weekly vaneomycin dosing with 20 mg/kg was sufficient in
high-flux dialysis. In 16 of our patients who received one weekly
dose of 20 mg/kg, mean pre-dialysis serum level at one week was
7.1 2.8 jxg/ml, significantly lower than that found by Pollard et
al (9.7 1.0, P < 0.02). This difference might be accounted for by
the earlier study's selection of patients with no residual renal
function, and perhaps by the significantly lower dose of dialysis
administered in that study. In any case, Pollard et al based their
dosing recommendations on a target trough vaneomycin level of 5
to 10 jxg/ml, which we feel, for reasons discussed above, to be
inadequate. In fact, five of their eight patients had serum vanco-
mycin levels lower than 10 jxg/ml after one week. In another
retrospective study of patients treated with both conventional and
high-flux dialysis using multiple dosing, Keller and associates
reached a similar conclusion to ours; that is, that administration of
500 mg doses after each dialysis is necessary to maintain thera-
peutically effective levels [15, 22, 24].
The dose of dialysis administered to our patients resulted in a
urea reduction ratio of 64 8%. There is reason to believe that
morbidity and mortality maybe reduced by more intensive dialysis
than this [75—771, which may become more and more common. A
higher dialysis dose might magnify the difference between single-
and multiple-dose vancomycin therapy by increasing dialytic re-
moval of vaneomycin, leading to even longer duration of subthera-
peutic levels in patients treated with single weekly doses.
A final consideration in comparing multiple and single weekly
dose vancomycin therapy is the difference in cost between the two
regimens; specifically, the potential for major increases in expense
with the use of more frequent dosing. Vancomycin has been
available as a generic preparation for some time, and is not
currently among the most expensive antibiotics (the cost to our
hospital pharmacy is $5.95/bOO mg) and the infrequent dosing
used in dialysis patients makes the cost of therapy almost incon-
sequential. The mean cost of the first (that is, most expensive)
week of multiple dose therapy in our patients (mean dose 2158
mg) was $12.84, and the mean weekly cost over the first four
weeks of multiple dose therapy (mean dose 1387 mg) was $8.25.
The mean cost of the first week of single weekly dose therapy
(mean dose 1198 mg) was $7.13. The small difference in cost
between single weekly and multiple dose therapy is thus not a
major factor in choosing between these regimens.
We conclude that in high-flux hemodialysis, a 20 mg/kg loading
dose of vancomycin followed by 500 mg doses after each dialysis
treatment achieves predictable, adequate and safe therapeutic
levels, does not lead to unacceptably high peaks, and does not
accumulate during long treatment courses. By contrast, once-
weekly vancomycin dosing results in subtherapeutic serum levels
after five to seven days, and should be abandoned in the high-flux
setting for the treatment of all but the most superficial bacterial
infections.
Acknowledgments
This material has been partially published in abstract form (JAm Soc
Nephrol 6:519; 1995) and was presented at the 28th Annual Meeting of the
American Society of Nephrology (San Diego, 1995). The authors are
grateful to Drs. Philip Goldwasser, John M. Quale, David Landman,
Geoffrey M. Berlyne, and Edmund Bourke for review of the manuscript
and helpful suggestions, to Carmine Caruso for technical assistance, and
to the Dialysis Nursing Staff of the Brooklyn VA Medical Center ftr
unflagging cooperation and assistance.
Reprint requests to Robert H. Barth, MD., Hemodialysis, VA Medical
center, 800 Poly Place, Brooklyn, New York 11209, USA. E-mail:
barth.rohert@brooklyn.va.gov
Barth and DeVincenzo: Vancomycin therapy in high-flux HD 935
References
1. BARCENAS CG, FULLER TJ, ELMS J, COHEN R, WHITE MG: Staphy-
lococcal sepsis in patients on chronic hemodialysis regimens: Intrave-
nous treatment with vancomycin given once weekly. Arch Intern Med
136:1131—1134, 1976
2. KEANE WF, SHAPIRO FL, RAIJ L: Incidence and type of infections
occurring in 445 chronic hemodialysis patients. Trans Am Soc Artif
Intern Organs 23:41—47, 1977
3. Nsouu KA, LAZARUS M, SCHOENBAUM SC, GOTTLIEB MN, LOWRIE
EG, SHOCAIR M: Bacteremic infection in hemodialysis. Arch Intern
Med 139:1255—1258, 1979
4. KESSLER M, HOEN B, MAYEUX D, HESTIN D, FONTENAILLE C:
Bactcremia in patients on chronic hemodialysis. A multicenter pro-
spective survey. Nephron 64:95—100, 1993
5. HIGGINS RM: Infections in a renal unit. Q JMed 70:41—51, 1989
6. BARTH RH, DEVINCENZO N: Bacteremia in hospital-based, high-flux
hemodialysis: Bacteriology, antibiotic susceptibilities, and relation to
vascular access. (abstract) JAm Soc Nephrol 5:432, 1994
7. WALTERS BAJ, MOLINA M, ROSENTHAL AF, DIDOMINC V, BANDER
Si: Incidence of bacteremia in hcmodialysis patients 1993-1994.
(abstract) JAm Soc Nephrol 6:567, 1995
8. MOELLERING RC JR, KROGSTAD Di, GREENBLATT DJ: Pharmacoki-
netics of vancomycin in normal subjects and in patients with reduced
renal function. Rev Infect Dis 3(Suppl):S230—S235, 1981
9. MATZKE GR, MCGORY RW, HALSTENSON CE, KEANE WF: Pharma-
cokinetics of vancomycin in patients with various degrees of renal
function. Antimicrob Agents Chemother 25:433—437, 1984
10. BLEVINS RD, HALSTENSON CE, SALEM NG, MATZKE GR: Pharmaco-
kinetics of vancomycin in patients undergoing continuous ambulatory
peritoneal dialysis. Antimicrob Agents Chemother 25:603—606, 1984
11. CUNHA BA, QUINTILIANI R, DEGLIN JM, IZARD MW, NIGHTINGALE
CH: Pharmacokinetics of vancomycin in anuria. Rev Infect Dis
3(Suppl):5269—5272, 1981
12. BARTH RH, DEVINCENZO N, ZARA AC, BERLYNE GM: Vancomycin
pharmacokinetics in high-flux hemodialysis. (abstract) J Am Soc
Nephrol 1:348, 1990
13. POLLARD TA, LAMPASONA V, AKKERMAN 5, TOM K, HOOKS MA,
MULLINS RE, MARONI BJ: Vancomycin redistribution: Dosing recom-
mendations following high-flux hemodialysis. Kidney mt 45:232—237,
1994
14. MATZKE GR, O'CONNELL MB, C0I.LINs AJ, KESHAVIAH PR: Dispo-
sition of vancomycin during hemofiltration. C/in Pharmacol Ther
40:425—430, 1986
15. KELLER F: Vancomycin administration to hemodialysis patients. (ab-
stract) C/in Nephrol 30:173, 1988
16. DE BOCK V, VERBEELEN D, MAES V, SENNESAEL J: Pharmacokinetics
of vancomycin in patients undergoing haemodialysis and haemofiltra-
tion. Nephrol Dial Transplant 4:635—639, 1989
17. LANESE DM, ALFREY PS, MOLITORIS BA: Markedly increased clear-
ance of vancomycin during hemodialysis using polysulfone dialyzers.
Kidney mt 35:1409—1412, 1989
18. BARTH RH, DEVINCENZO N, BERIYNE GM: Revised vancomycin
dosing schedule for high-flux hemodialysis. JAm Soc Ivephrol 2:314,
1991
19. TORRAS J, CAO C, RIVAS MC, CANO M, FERNANDEZ E, MoKF0LIu i:
Pharmacokinetics of vancomycin in patients undergoing hemodialysis
with polyacrylonitrile. C/in Nephrol 36:35—41, 1991
20. QUALE JM, O'HALLORAN iJ, DEVINCENZO N, BARTh RH: Removal of
vancomycin by high-flux hemodialysis membranes. Antimicrob Agents
Chemother 36:1424—1426, 1992
21. DES0I CA, SAIIM DF, UMANS JG: Vaneomycin elimination during
high liux hemodialysis: Kinetic model and comparison of four mem-
branes. Am J Kidney Dis 20:354—360, 1992
22. BOHIER i, REETZE-BONORDEN P, KELLER E, KRAMER A, SCHOLL-
MEYER PJ: Rebound of plasma vancomyein levels after haemodialysis
with highly permeable membranes. EurJ C/in Pharmacol 42:635—640,
1992
23. ALWAKEEL J, NAJJAR TA, AL-YAMANI MJ, HURAIB 5, AL-HAIDER A,
ABUTOAISHA H: Comparison of the effects of three haemodialysis
membranes on vaneomyein disposition. mt Urol Nephrol 26:223—228,
1994
24. KELLER F, HORSTENSMEYER C, LOOBY M, BORNER K, POMMER W,
ERDMANN K, GIEHL M: Vancomycin dosing in haemodialysis patients
and Bayesian estimate of individual pharmacokinetic parameters. mt
JArtif Organs 17:19—26, 1994
25. TOUCIIETTE MA, PATEL RV, ANANDAN iV, DUMLER F, ZAROwITZ Bi:
Vancomycin removal by high-flux polysulfone hemodialysis mem-
branes in critically ill patients with end-stage renal disease. Am J
Kidney Dis 26:469—474, 1995
26. ROTSCHAFER JC, CROSSLEY K, ZASKE DE, MEAD K, SAWCHUK RJ,
SOLEM LD: Pharmacokinetics of vaneomycin: Observations in 28
patients and dosage recommendations. Antimicrob Agents Chemother
22:391—394, 1982
27. WEST RE: Comment: Monitoring vancomycin therapy. DICP 21:467,
1987
28. MOELLERING RC: Monitoring serum vancomycin levels: Climbing the
mountain because it is there? C/in Infect Dis 18:544—546, 1994
29. POHLOD Di, SARAVOLATZ, LD, SOMERVILLE MM: Comparison of
fluorescence polarization immunoassay and bioassay of vancomycin.
J C/in Microbial 20:159—161, 1984
30. EDWARDS DJ, PANCORBO 5: Routine monitoring of scum vaneomycin
concentrations: Waiting for proof of its value. C/in Pharm 6:652—654,
1987
31. FREEMAN CD, QUINTILIANI R, NIGHTINGALE CH: Vancomycin ther-
apeutic drug monitoring: Is it necessary? Ann Pharmacother 27:594—
598, 1993
32. CANTI.IJ TG, YAMANAKA-YUEN NA, LIETMAN PS: Serum vancomyein
concentrations: Reappraisal of their clinical value. C/in Infect Dis
18:533—543, 1994
33. LEADER WG, CHANDLER MH, CASTIGLIA M: Pharmacokinetic optimi-
sation of vancomycin therapy. C/in Pharmacokinet 28:327—342, 1995
34. MACGOWAN A, LOVERING A, WHITE L, REEVES D: Why monitor peak
vaneomyein concentrations? Lancet 345:645, 1995
35. DUFFULL SB, BEGG EJ: Why monitor peak vancomycin concentra-
tions? Lancet 345:646, 1995
36. COOK FV, FARRAR WE JR: Vancomycin revisited. Ann Intern Med
88:813—818, 1978
37. GREENBERG RN, BENES CA: Time-kill studies with oxacillin, vaneo-
mycin, and teicoplanin versus Staphylococcus aureus. J Infect Dis
161:1036—1037, 1990
38. BAILEY EM, RYBAK Mi, KAATZ GW: Comparative effect of protein
binding on the killing activities of teicoplanin and vancomyein.
Antimicrob Agents Chemother 35:1089—1092, 1991
39. ACKERMAN BH, VANNIER AM, EUDY EB: Analysis of vancomycin
time-kill studies with Staphylococcus species by suing a curve stripping
program to describe the relationship between concentration and
pharmacodynamie response. Antimicrob Agents Chemother 36:1766 —
1769, 1992
40. SAUNDERS NJ: Why monitor peak vancomycin concentrations? Lancet
344:1748—1750, 1994
41. BRUMMET RE: Ototoxicity of vaneomyein and analogues. Oto/atygol
C/in NAm 26:821—828, 1993
42. ACKERMAN BH, VANNIER AM: Necessity of a loading dose when using
vaneomyein in critically ill patients. J Antimicrob Chemother 29:460—
461, 1992
43. DR HooG M, MouToN iW, VAN DEN ANKER iN: Why monitor peak
vaneomyein concentrations? Lancet 345:646, 1994
44. DUFFULL SB, BEGG Ei: Why monitor peak vaneomyein concentra-
tions? Laneet 345:646, 1994
45. WATANAKUNAKORN C: Mode of action and in vitro activity of vanco-
myein. JAntimicrob Chemother 14(Suppl D):7—18, 1984
46. TRUnEI.u JENSEN K, SCHØNHEYDER H, PERS C, FRØLUND THOMSEN V:
In vitro activity of teicoplanin and vancomycin against Gram-positive
bacteria from human clinical and veterinary sources. APMJS 100:543—
552, 1992
47. SCHWALBE RS, SIAI'IvIoN iT, GILLIGAN PH: Emergence of vanco-
mycin resistance in coagulase-negative staphylococci. N EngI J Med
316:927—931, 1987
48. BIAVASCO F, GIOvANEI-II E, MONTANARI MP, LUPIDI R, VARALDO
PE: Development of in vitro resistance to glycopeptide antibiotics:
Assessment in staphylococci of different species. J Antimicrob Che-
mother 27:71—79, 1991
936 Barth and DeI/incenzo: Vancomycin therapy in high-flux HD
49. SHETH NK, FRANSON TR, SOHNLE PG: Influence of bacterial adher-
ence to intravascular catheters on in vitro antibiotic susceptibility.
Lancet 2:1266—1268, 1985
50. EVANS RC, HOLMS CJ: Effect of vancomycin hydrochloride on Staph-
ylococcus epidermidis biofllm associated with silicone elastomer. Anti-
microb Agents Chemother 31:889—894, 1987
51. NAYLOR PT, MYRVIK QN, GRISTINA A: Antibiotic resistance of
biomaterial-adherent coagulase-negative and coagulase-positive
staphylococci. Cl/n Orthop 261:126—133, 1990
52. CHUARD C, VAUDAUX P, WALDVOOEL FA, LEW DP: Susceptibility of
Staphylococcus aureus growing on fibronectin-coated surfaces to bac-
tericidal antibiotics. Antimicrob Agents Chemother 37:625—632,1993
53. WEBB LX, HOLMAN J, DE ARAUJO B, ZACCARO DJ, GORDON ES:
Antibiotic resistance in staphylococci adherent to cortical bone.
J Orthop Trauma 8:28—33, 1994
54. BAILEY EM, RYKBAK MJ, KAATZ GW: Comparative effect of protein
binding on the killing activities of teicoplanin and vancomycin.
.4ntimicrob Agents Chemother 35:1089—1092, 1991
55. KROPEC A, DASCHNER FD: Penetration into tissues of various drugs
active against gram-positive bacteria. J Antimicrob Chemot her
27(Suppl B):9—15,1991
56. LAMER C, DR BECO V, SOLER P, CALVAT S, FAGON J-Y, DOMBRET
M-C, FARINOTrI R, CHASTRE J, GIBERT C: Analysis of vancomycin
entry into pulmonary lining fluid by bronchoalveolar lavage in criti-
cally ill patients. Antimicrob Agents Chemother 37:281—286, 1993
57. WILSON KJ, MADER JT: Concentrations of vancomycin in bone and
serum of normal rabbits and those with osteomyelitis. Antimicrob
Agents Chemother 25:140—141, 1984
58. MORSE GD, NAIRN DK, BERTINO JS, WALSHE JJ: Overestimation of
vancomycin concentrationsutilizing fluorescence polarization immu-
noassay in patients on peritoneal dialysis. Ther Drug Monit 9:212—215,
1987
59. WHITE LO, EDWARDS R, HOLT HA, LOVERING AM, FINCH RG,
REEVES DS: The in vitro degradation at 37 degrees C of vancomycin
in serum, CAPD fluid and phosphate-buffered saline. J Antimicrob
Chemother 22:739—745, 1988
60. ANNE L, Hu M, CHAN K, COLIN 1, GOTFWALD K: Potential problem
with fluorescence polarization immunoassay cross-reactivity to vanco-
mycin degradation product CDP-1: Its detection insera of renally
impaired patients. Ther Drug Monit 11:585—591, 1989
61. HORTIN GL, LANDT M, WIIHITE T, SMITH CH: Cross-reactivity of a
vancomycin degradation product in three immunoassays of vancomy-
cm. C/in Chem 37:2009, 1991
62. GERACI JE, HEILMAN FR, NICIIOLS DR, WELLMAN WE: Antibiotic
therapy of bacterial endocarditis. VII. Vancomycin for acute micro-
coccal endocarditis. Proc Staff Meetings Mayo C/in 33:172—181, 1958
63. SCHAAD UB, NELSON JD, MCCRACKEN GH JR: Pharmacology and
efficacy of vancomycin for staphylococcal infections in children. Rev
Infect Dis 3(Suppl):S282—S288, 1981
64. HEALY DP, POLK RE, GARSON ML, ROCK DT, COMSTOCK TJ:
Comparison of steady-state pharmacokinetics of two dosage regimens
of vancomycin in normal volunteers. Antimicrob Agents Chemother
31:393—397, 1987
65. GLEW R: Vancomycin, in Infectious Diseases, edited by GORBACH SL,
BARTLE1-r JG, BLACKLOW NR, Philadelphia, WB Saunders, 1992, pp
231—239
66. ZIMMERMANN AE, KATONA BG, PLAISANCE KI: Association of van-
comycin serum concentrations with outcomes in patients with gram-
positive bacteremia. Pharmacotherapy 15:85—91, 1995
67. MULHERN JG, BRADEN GL, O'SHEA MH, MADDEN RL, LIPKOWITZ
GS, GERMAIN MJ: Trough serum vancomycin levels predict the
relapse of gram-positive peritonitis in peritoneal dialysis patients.
Am J Kidney Dis 25:611—615, 1995
68. MOELLERING RC JR: Pharmacokinetics of vancomycin. J Antimicrob
Chemother 14(Suppl D):43—52, 1984
69. FEruTY R: Vancomycin and teicoplanin, in The Principles and Practice
ofInfectious Disease (3rd ed), edited by MANDELL GL, DOUGLAS RG
JR, BENNETF JE, New York, Churchill Livingstone, 1989, pp 317—323
70. SHAY DK, MALONEY SA, MONTECALVO M, BANERJEE 5, WORMSER
GP, ARDUINO MJ, BLAND LA, JARVIS WR: Epidemiology and mor-
tality risk of vancomycin-resistant enterococcal bloodstream infec-
tions. J Infect Dis 172:993—1000, 1995
71. CENTERS FOR DISEASE CONTROL AND PREVENTION: Recommendations
for preventing the spread of vancomycin resistance: Recommenda-
tions of the Hospital Infection Control Practices Advisory Committee
(HICPAC). MMWR 44(RR-12):1—13, 1995
72. SMALL PM, CHAMBERS HF: Vancomycin for Staphylococcus aureus
endocarditis in intravenous drug abusers. Antimicrob Agents Che-
mother 34:1227—1231, 1990
73. LEVINE DP, FROMM BS, REDDY BR: Slow response to vancomycin or
vancomycin plus rifampin in methicillin-resistant Staphylococcus au-
reus endocarditis. Ann Intern Med 115:674—680, 1991
74. MORTARA LA, BAYER AS: Staphylococcus aureus bacteremia and
endocarditis: New diagnostic and therapeutic concepts. Infect Dis C/in
!'IAm 7:53—68, 1993
75. OWEN WE JR, LEW NL, LIU Y, LOWRIE EG, LAZARUS JM: The urea
reduction ratio and serum albumin concentration as predictors of
mortality in patients undergoing hemodialysis. N Engl J Med 329:
1001—1006, 1993
76. PARKER T: Hemodialysis adequacy, in Principles and Practice of
Dialysis, edited by HENRICH WL, Baltimore, Williams & Wilkins,
1994, pp 63—75
77. BARTH RH: Pros and cons of short, high efficiency, and high flux
dialysis, in Replacement of Renal Function by Dialysis (4th ed), edited
by WINCHESTER JF, JACOBS C, KIELLSTRAND CM, Kocn KM, Dor-
drecht, Kluwer, 1996
